Stockreport

GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy [Seeking Alpha]

GSK plc American Depositary Shares (Each representing two Ordinary Shares)  (GSK) 
US:NYSE Investor Relations: gsk.com/en-gb/investors
PDF Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no sign of slowing down. GSK's franchise only faces minor patent cliffs over the next [Read more]